Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT02042443
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-28T10:36:48.796588+00:00
Published At
2017-08-10T00:00:00+00:00
Record Updated At
2017-09-12
Results Posted At
2017-08-10
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Adult Cholangiocarcinoma", "Advanced Adult Hepatocellular Carcinoma", "BCLC Stage C Adult Hepatocellular Carcinoma", "BCLC Stage D Adult Hepatocellular Carcinoma", "Hilar Cholangiocarcinoma", "Localized Non-Resectable Adult Liver Carcinoma", "Recurrent Adult Liver Carcinoma", "Recurrent Childhood Liver Cancer", "Recurrent Extrahepatic Bile Duct Carcinoma", "Recurrent Gallbladder Carcinoma", "Stage II Gallbladder Cancer", "Stage III Childhood Hepatocellular Carcinoma", "Stage IIIA Gallbladder Cancer", "Stage IIIB Gallbladder Cancer", "Stage IV Childhood Hepatocellular Carcinoma", "Stage IV Distal Bile Duct Cancer", "Stage IVA Gallbladder Cancer", "Stage IVB Gallbladder Cancer", "Unresectable Extrahepatic Bile Duct Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2017-09-12"
protocolSection.identificationModule.nctId
"NCT02042443"
protocolSection.identificationModule.officialTitle
"Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
"2017-08-10"

Study condition terms

  • Adult Cholangiocarcinoma (protocolSection.conditionsModule.conditions)
  • Advanced Adult Hepatocellular Carcinoma (protocolSection.conditionsModule.conditions)
  • BCLC Stage C Adult Hepatocellular Carcinoma (protocolSection.conditionsModule.conditions)
  • BCLC Stage D Adult Hepatocellular Carcinoma (protocolSection.conditionsModule.conditions)
  • Hilar Cholangiocarcinoma (protocolSection.conditionsModule.conditions)
  • Localized Non-Resectable Adult Liver Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Adult Liver Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Childhood Liver Cancer (protocolSection.conditionsModule.conditions)
  • Recurrent Extrahepatic Bile Duct Carcinoma (protocolSection.conditionsModule.conditions)
  • Recurrent Gallbladder Carcinoma (protocolSection.conditionsModule.conditions)
  • Stage II Gallbladder Cancer (protocolSection.conditionsModule.conditions)
  • Stage III Childhood Hepatocellular Carcinoma (protocolSection.conditionsModule.conditions)
  • Stage IIIA Gallbladder Cancer (protocolSection.conditionsModule.conditions)
  • Stage IIIB Gallbladder Cancer (protocolSection.conditionsModule.conditions)
  • Stage IV Childhood Hepatocellular Carcinoma (protocolSection.conditionsModule.conditions)
  • Stage IV Distal Bile Duct Cancer (protocolSection.conditionsModule.conditions)
  • Stage IVA Gallbladder Cancer (protocolSection.conditionsModule.conditions)
  • Stage IVB Gallbladder Cancer (protocolSection.conditionsModule.conditions)
  • Unresectable Extrahepatic Bile Duct Carcinoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.